Anavex Life Sciences (AVXL) Profit After Tax (2016 - 2025)

Anavex Life Sciences (AVXL) has 10 years of Profit After Tax data on file, last reported at -$5.7 million in Q4 2025.

• For the quarter ending Q4 2025, Profit After Tax rose 53.09% year-over-year to -$5.7 million; the trailing twelve-month figure through Dec 2025 stood at -$39.9 million (up 14.08% YoY), and the FY2025 full-year result was -$46.4 million, down 7.85% from the prior year.
• Profit After Tax advanced to -$5.7 million in Q4 2025, from -$9.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$5.7 million in Q4 2025 to a low of -$14.3 million in Q3 2022.
• A 5-year average of -$11.0 million and a median of -$11.2 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 96.45% in 2021 and surged 53.09% in 2025, its largest moves.
• Tracing AVXL's Profit After Tax over 5 years: stood at -$10.9 million in 2021, then dropped by 19.2% to -$13.0 million in 2022, then surged by 33.53% to -$8.6 million in 2023, then tumbled by 40.47% to -$12.1 million in 2024, then surged by 53.09% to -$5.7 million in 2025.
• Business Quant data shows AVXL's Profit After Tax at -$5.7 million in Q4 2025, -$9.8 million in Q3 2025, and -$13.2 million in Q2 2025.